Comparison of fondaparinux and enoxaparin in acute coronary syndromes - The New England Journal of Medicine - 2006
Brief Summary:
Among patients with NSTE-ACS, fondaparinux is non-inferior to enoxaparin in preventing death, myocardial infarction, or refractory ischemia.Reference:
http://www.ncbi.nlm.nih.gov/pubmed/16537663
Comments
Post a Comment
Drop your thoughts here, we would love to hear from you